Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

INTRODUCTION: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kircik, Leon, Fowler, Joseph, Weiss, Jonathan, Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120628/
https://www.ncbi.nlm.nih.gov/pubmed/27573260
http://dx.doi.org/10.1007/s13555-016-0139-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120628/
https://www.ncbi.nlm.nih.gov/pubmed/27573260
http://dx.doi.org/10.1007/s13555-016-0139-0

Ejemplares similares